Randomized trial · people
Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a small controlled trial, a short teriparatide course added to standard care helped more MRONJ lesions resolve than placebo, with mostly mild side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 34
- Published
- 2020
- Journal
- J Clin Oncol
What they tested
The team tested whether a short course of teriparatide helps established medication-related osteonecrosis of the jaw (MRONJ, jaw bone damage linked to antiresorptive and antiangiogenic medicines) heal better than placebo.
How the study was done
A double-blind, randomized, placebo-controlled trial in 34 people with established MRONJ, who had 47 separate lesions between them. They got 8 weeks of daily teriparatide shots under the skin (20 µg/day) or placebo shots (a dummy injection), on top of calcium, vitamin D and standard care, and were followed for 12 months.

What they found
Lesions healed at a higher rate in people on teriparatide than in those on placebo. At 52 weeks, 45.4% of teriparatide-treated lesions had resolved, versus 33.3% of lesions on placebo. The teriparatide group also had smaller bony defects at week 52 (odds ratio 8.1). Side effects were about as common in both groups and mostly mild, such as nausea, poor appetite and muscle or bone pain.
What it doesn’t show
This was a small trial of 34 people with one 8-week treatment course and 12 months of follow-up. Results were counted per lesion, and everyone also got calcium, vitamin D and standard care.
The paper
Sim et al. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol. 2020.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)Meta-analysis · people · 2024
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: more bony union at 6 months than zoledronate after PLIFRandomized trial · people · 2022
- Teriparatide: fewer new vertebral fractures than risedronate in VERORandomized trial · people · 2018
- Teriparatide then denosumab: spine density up 18.3% over 4 yearsRandomized trial · people · 2015
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.